Non-interventional observational study, following the first year of SLIT-Tablet treatment with GRAZAX® or ITULAZAX® to assess persistence and adherence among patients in Norwegian primary care
This prospective, non-interventional study of 204 patients in Norwegian primary care demonstrates that SLIT-tablet treatment (Grazax® or Itulazax®) achieves high one-year persistence and adherence, leading to significant symptom improvement and safety, thereby supporting the effective delivery of disease-modifying allergic rhinitis therapy in routine general practice.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Allergic rhinitis, commonly known as hay fever, is a widespread condition where the immune system overreacts to harmless particles like pollen, causing sneezing, itchy eyes, and a runny nose. While standard medicines like antihistamines can temporarily quiet these symptoms, they do not change the underlying immune response. For decades, the only treatment capable of altering the course of the disease has been allergen immunotherapy, a process that gradually trains the body to tolerate the trigger. In recent years, a specific form of this therapy has emerged that uses dissolving tablets placed under the tongue, allowing patients to take their medicine at home after an initial supervised dose. However, for this treatment to work, patients must commit to taking it daily for several years, a requirement that often leads to people stopping too soon. The question facing doctors is whether this long-term commitment can be successfully managed outside of specialized allergy clinics, within the everyday setting of a general practitioner's office.
To answer this, researchers in Norway conducted a real-world observation of patients starting treatment with two specific sublingual tablets, one for grass pollen and one for birch pollen. They followed 204 individuals, ranging in age from six to sixty-five, across seventeen different general practices. The goal was not to test a new drug, but to see how well the existing treatment worked when managed by regular family doctors. Over the course of one year, the medical team checked in with patients at scheduled intervals to track whether they continued taking the tablets, how well they stuck to the daily schedule, and how their symptoms changed during the pollen season. They also monitored any side effects and asked patients how satisfied they were with the results.
The study found that the treatment was highly successful in a primary care setting. After one year, 78 percent of the patients were still taking their medication, a figure that surpassed the researchers' target of 70 percent. This persistence rate suggests that general practitioners can effectively support patients through the difficult early stages of therapy. Among those who stayed on the treatment, adherence was excellent, with more than 90 percent of patients reporting that they took their tablet every single day. When patients did miss a dose, the most common reason was simply forgetting, rather than the treatment causing unpleasant side effects or being difficult to obtain.
As the pollen season progressed, the patients reported significant relief from their symptoms. At the start of the study, most people suffered from moderate to severe nasal and eye irritation. By the end of the year, the number of people reporting severe symptoms had dropped dramatically, and a much larger group reported having no symptoms at all. This improvement was accompanied by a noticeable decrease in the use of other medicines. Patients relied less on oral antihistamines and nasal sprays to manage their discomfort, indicating that the immunotherapy tablets were effectively controlling the allergy itself. The safety profile of the treatment remained consistent with what is already known: while nearly half of the patients experienced some side effect, almost all were mild or moderate, such as itching in the mouth or throat. No serious safety concerns emerged, and no patients required hospitalization due to the treatment.
The results also highlighted a strong sense of satisfaction among those involved. At the end of the year, the vast majority of patients described themselves as very satisfied or satisfied with their treatment, a sentiment echoed by the doctors who monitored them. The study suggests that the continuity of care provided by a family doctor, who sees the patient regularly and can address concerns immediately, plays a crucial role in keeping patients on track. This approach mirrors the support structure found in specialist clinics, proving that the specialized care needed for long-term allergy treatment does not have to be confined to hospitals. The findings indicate that when supported by structured follow-up, general practices can successfully deliver disease-modifying treatments, offering a practical path for more people to achieve long-term relief from seasonal allergies.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.